Servier Laboratories (Ireland) Ltd announce that Lipertance will be available for prescription from November 2021

Servier Laboratories (Ireland) Ltd is delighted to announce that Lipertance, the combination of atorvastatin, perindopril and amlodipine1, will be available for prescription from November 2021 and is listed as a PCRS reimbursable product.

Lipertance® is the first Statin + ACEi + Calcium Channel blocker combination available in Ireland2.

Servier continue to add to their range of Single Pill Combination solutions for the management of patients with cardiovascular disease3. The arrival of Lipertance, in particular, offers greater intensification of blood pressure (BP) control for patients on a statin1. It follows the recent launch (Feb 2021) of , Lipercosyl the statin/ACEi combination of atorvastatin and perindopril4.

Like Lipercosyl®, Lipertance® controls high cholesterol and hypertension in unison1, helping patients with these cardiovascular risk factors to meet their target blood pressure5 and low-density lipoprotein cholesterol (LDL-C)6  and thereby helping to avoid cardiovascular outcomes1.

Atorvastatin has been shown to reduce concentrations of LDL-C by up to 49%7. Perindopril and amlodipine reduce BP by up to 33.7/17.1mmHg helping patients reach lower targets8. Perindopril and amlodipine’s antihypertensive effect is sustained for at least 24 hours and atorvastatin is a long-acting statin, ensuring true 24hr control from a single daily dose1, 9.

Furthermore, it has been demonstrated in the large ASCOT study (n=19,259 patients) that a combination of statin with amlodipine +/- perindopril yields a 53% relative risk reduction in fatal coronary events and non-fatal MI p<0.00011.

Prescribing the 3 agents in a Single-Pill Combination offers patients better efficacy, tolerability and adherence10-13.  Lipertance is taken one tablet daily in the morning before breakfast.1

Lipertance® is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination. 1

Should you require any further information, please contact Servier on 01 6638110, or refer to the full Summary of Product Characteristics on www.medicines.ie

Leave a Reply

Your email address will not be published.

Please Confirm

This website is only for the eyes of medical professionals. Are you a medical professional?